FY2019 EPS Estimates for Eli Lilly and Company (LLY) Decreased by Analyst
Eli Lilly and Company (NYSE:LLY) – Research analysts at SunTrust Banks decreased their FY2019 earnings per share (EPS) estimates for Eli Lilly and in a research report issued on Wednesday. SunTrust Banks analyst J. Boris now anticipates that the company will earn $4.67 per share for the year, down from their prior forecast of $4.79. SunTrust Banks also issued estimates for Eli Lilly and’s FY2020 earnings at $5.42 EPS and FY2021 earnings at $6.19 EPS.
LLY has been the subject of several other reports. BMO Capital Markets set a $71.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, April 25th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Berenberg Bank reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $92.00 price objective on shares of Eli Lilly and in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $88.27.
ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/18/fy2019-eps-estimates-for-eli-lilly-and-company-lly-decreased-by-analyst.html.
Shares of Eli Lilly and (NYSE LLY) traded down 0.623% during midday trading on Friday, reaching $77.315. The company’s stock had a trading volume of 2,528,916 shares. The stock has a 50-day moving average of $82.55 and a 200 day moving average of $81.88. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72. The company has a market cap of $81.57 billion, a price-to-earnings ratio of 33.455 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the company posted $0.86 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.67%. Eli Lilly and’s dividend payout ratio is 90.04%.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock worth $55,845,287 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Ronna Sue Cohen raised its stake in Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares in the last quarter. Accredited Investors Inc. raised its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares in the last quarter. Sunbelt Securities Inc. raised its stake in Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares in the last quarter. Finally, Pillar Pacific Capital Management LLC raised its stake in Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 75.59% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.